This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Roche Glycart Ag. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Christoph Lampert: Innovator in Bispecific Antibody Technology
Introduction
Christoph Lampert is a prominent inventor based in Zurich, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies. His innovative work has the potential to advance therapeutic options in various medical applications.
Latest Patents
One of Christoph Lampert's notable patents is titled "DR5—FAP bispecific death receptor agonistic antibodies." This invention relates to bispecific antibodies that comprise a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen. The patent also covers methods for their production, pharmaceutical compositions containing these antibodies, and their various uses. He holds 1 patent in this area.
Career Highlights
Christoph Lampert is currently associated with Roche Glycart AG, a leading company in the field of biopharmaceuticals. His work at Roche Glycart AG has allowed him to focus on cutting-edge research and development in antibody technology. His contributions have been instrumental in advancing the company's innovative projects.
Collaborations
Throughout his career, Christoph has collaborated with several talented professionals, including Peter Bruenker and Claudia Ferrara Koller. These collaborations have fostered a dynamic research environment, leading to significant advancements in their field.
Conclusion
Christoph Lampert's work in bispecific antibody technology exemplifies the innovative spirit of modern biotechnology. His contributions continue to pave the way for new therapeutic solutions in medicine.